Sugentech Inc. Stock price

Equities

A253840

KR7253840003

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. 06:00:00 2024-02-27 pm EST 5-day change 1st Jan Change
6,490 KRW +0.93% Intraday chart for Sugentech Inc. -3.99% -16.26%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2021 77.2B 57.9M Sales 2022 101B 76.05M Capitalization 165B 124M
Net income 2021 36.15B 27.11M Net income 2022 26.72B 20.04M EV / Sales 2021 1.62 x
Net cash position 2021 91.49B 68.62M Net cash position 2022 93.57B 70.18M EV / Sales 2022 0.71 x
P/E ratio 2021
6.89 x
P/E ratio 2022
6.73 x
Employees 137
Yield 2021 *
-
Yield 2022
1.48%
Free-Float 84.07%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023. CI
Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023. CI
Sugentech Inc.'s Equity Buyback announced on March 29, 2023, has closed with 1,453,532 shares, representing 9.11% for KRW 11,999.87 million. CI
Sugentech Inc.'s Equity Buyback Plan Extended till December 28, 2023. CI
Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023. CI
Tranche Update on Sugentech Inc.'s Equity Buyback Plan announced on March 29, 2023. CI
Sugentech Inc. announces an Equity Buyback for KRW 12,000 million worth of its shares. CI
Sugentech Inc. authorizes a Buyback Plan. CI
Sugentech Inc.(KOSDAQ:A253840) added to S&P Global BMI Index CI
Sugentech Inc. announced that it has received KRW 34.9997715 billion in funding from a group of investors CI
Sugentech Inc. announced that it expects to receive KRW 34.9997715 billion in funding from a group of investors CI
Avellino and Sugentech Announce Strategic Collaboration CI
Sugentech Inc. announced that it has received KRW 10 billion in funding from a group of investors CI
Sugentech Inc. announced that it expects to receive KRW 10 billion in funding from a group of investors CI
Samsung Securities Co.,Ltd. acquired 3.41% stake in Sugentech Incorporated from The Innopolis Job Creation Fund, a fund of Innopolis Partners LLC for KRW 4.9 billion. CI
More news
1 day+0.93%
1 week-3.99%
Current month-2.11%
1 month-2.84%
3 months+6.39%
6 months-4.84%
Current year-16.26%
More quotes
1 week
6 330.00
Extreme 6330
6 790.00
1 month
6 330.00
Extreme 6330
7 050.00
Current year
6 330.00
Extreme 6330
7 980.00
1 year
5 920.00
Extreme 5920
11 200.00
3 years
5 920.00
Extreme 5920
36 400.00
5 years
4 510.00
Extreme 4510
65 800.00
10 years
4 510.00
Extreme 4510
65 800.00
More quotes
Managers TitleAgeSince
Founder 57 11-12-08
Founder 49 11-12-08
Founder 59 11-12-08
Members of the board TitleAgeSince
Founder 59 11-12-08
Director of Finance/CFO 46 -
Founder 57 11-12-08
More insiders
Date Price Change Volume
24-02-28 6,490 +0.93% 22,061
24-02-27 6,430 -1.53% 75,585
24-02-26 6,530 -1.80% 38,612
24-02-23 6,650 -0.30% 42,770
24-02-22 6,670 -1.33% 38,531

End-of-day quote Korea S.E., February 27, 2024

More quotes
Sugentech Incorporate is a Korea-based company mainly engaged in the production and sale of in-vitro diagnostic test reagents. The Company is involved in the manufacturing and sale of in vitro diagnostic test reagents, point-of-care testing (POCT) products, folic acid products under the name of SOLGAR, as well as molecular diagnostic reagents. The in vitro diagnostic test reagents are for personal use and are sold under the name SUREARLY. The POCT products are for professional use and are sold under the name INCLIX. In addition, the Company is engaged in therapeutic drug monitoring, as well as drug analysis method development. The Company distributes its products within the domestic market and to overseas markets, including Indonesia.
More about the company
  1. Stock
  2. Equities
  3. Stock Sugentech Inc. - Korea S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW